Page 3 - சான் பிரான்சிஸ்கோ வா மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Omecamtiv mecarbil significantly reduces hospitalizations among patients with severe heart failure The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart s pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology s 70th Annual Scientific Session. Omecamtiv mecarbil works by improving the ability for heart muscle cells to contract and operates through a different biological pathway than any of the current heart failure medications. The research is an extended analysis of data from GALACTIC-HF, a trial involving more than 8,200 participants that found omecamtiv mecarbil significantly improved outcomes in terms of a composite of cardiovascular death or heart failure events among patients with heart failure with reduced e

United statesSan franciscoJohnr teerlinkEmily hendersonSan francisco va medical centerUniversity of californiaAmerican college of cardiologyAmerican collegeAnnual scientificHeart failureஒன்றுபட்டது மாநிலங்களில்சான் பிரான்சிஸ்கோஎமிலி ஹென்டர்சன்சான் பிரான்சிஸ்கோ வா மருத்துவ மையம்பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியாஅமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்